Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zoetis (ZTS – Research Report), Dexcom (DXCM – Research Report) and Gilead Sciences (GILD – Research Report).
Zoetis (ZTS)
Barclays analyst Balaji Prasad maintained a Buy rating on Zoetis on February 9 and set a price target of $255.00. The company’s shares closed last Friday at $197.32, close to its 52-week high of $201.92.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of
Zoetis has an analyst consensus of Strong Buy, with a price target consensus of $232.60.
See Insiders’ Hot Stocks on TipRanks >>
Dexcom (DXCM)
In a report issued on February 9, Matt Miksic from Barclays maintained a Hold rating on Dexcom, with a price target of $138.00. The company’s shares closed last Friday at $120.47.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $144.85.
Gilead Sciences (GILD)
In a report released today, Carter Gould from Barclays maintained a Hold rating on Gilead Sciences, with a price target of $80.00. The company’s shares closed last Friday at $73.67, close to its 52-week low of $72.81.
According to TipRanks.com, Gould is a 5-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $87.56, representing a 18.6% upside. In a report issued on February 6, Wells Fargo also maintained a Hold rating on the stock with a $84.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZTS:
